New Technologies And Approaches Spur Industry Interest In Plant-Derived Drugs

In Plant-Derived Drugs Author: Steven Benowitz Date: February 5, 1996 Historically, industry interest in plant-derived pharmaceuticals has waxed and waned. But greatly improved drug-screening technologies and a concern over disappearing Third World resources (and potential sources of medicines) have fueled a resurgence of drug-industry interest in natural products and plant-derived drugs in recent years. Optimistic: James Miller of the Missouri Botanical Garden sees new technology as key to

Written bySteven Benowitz
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

In Plant-Derived Drugs Author: Steven Benowitz
Date: February 5, 1996

Historically, industry interest in plant-derived pharmaceuticals has waxed and waned. But greatly improved drug-screening technologies and a concern over disappearing Third World resources (and potential sources of medicines) have fueled a resurgence of drug-industry interest in natural products and plant-derived drugs in recent years.

James Miller Optimistic: James Miller of the Missouri Botanical Garden sees new technology as key to industry interest in plant-based pharmaceuticals. Photo: Steven Goldblatt Yet not everyone agrees that this renewed industry enthusiasm for going out to the field to seek plant-based drugs is widespread or long-term. Rather, they contend, labor-intensive plant-collection methods are being supplanted by newer, laboratory-based chemistry techniques. In fact, one executive at a major pharmaceutical firm discourages students from pursuing careers in natural products chemistry, believing that new technologies such as combinatorial chemistry are the wave of the future.

Every year, thousands of naturally ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies